Home » Topics » Disease categories and therapies » Substance use and poisoning

Substance use and poisoning
RSS

Adamis Pharmaceuticals receives a complete response letter regarding Zimhi

Nov. 26, 2019

Binging brains give themselves away

Nov. 26, 2019

Diabetes drug eases nicotine withdrawal

Nov. 14, 2019

New phase II trial studies suvorexant for comorbid sleep disorder and alcohol dependence

Oct. 24, 2019

Dosing begins in NIH-funded phase II proof-of-concept study of ANS-6637

Oct. 18, 2019

AstraZeneca initiates first-in-human study of AZD-4041 in healthy volunteers

Oct. 15, 2019

Humanetics' development of radioprotectant BIO-301 supported by DoD cooperative research agreement

Oct. 2, 2019

NIDA grant supports Kinoxis' development of KNX-100 for opioid withdrawal

Oct. 1, 2019

Emergent BioSolutions, Indivior win NIH grants to study drugs for opioid use disorder

Sep. 30, 2019

NIDA award to support Ensysce's development of opioid use disorder product

Sep. 27, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...
Gene replacement rescues autism-related phenotypes in mice
BioWorld Science
Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...